CA2830933A1 - Methods for treating or preventing urological inflammation - Google Patents

Methods for treating or preventing urological inflammation Download PDF

Info

Publication number
CA2830933A1
CA2830933A1 CA2830933A CA2830933A CA2830933A1 CA 2830933 A1 CA2830933 A1 CA 2830933A1 CA 2830933 A CA2830933 A CA 2830933A CA 2830933 A CA2830933 A CA 2830933A CA 2830933 A1 CA2830933 A1 CA 2830933A1
Authority
CA
Canada
Prior art keywords
hyaluronan
kda
group
compound
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2830933A
Other languages
English (en)
French (fr)
Inventor
Glenn D. Prestwich
Siam Oottamasathien
Wanjian Jia
Lindsi Mccoard
Won Yong Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/069,860 external-priority patent/US8343942B2/en
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of CA2830933A1 publication Critical patent/CA2830933A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2830933A 2011-03-23 2012-03-23 Methods for treating or preventing urological inflammation Abandoned CA2830933A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/069,860 2011-03-23
US13/069,860 US8343942B2 (en) 2008-04-04 2011-03-23 Methods for treating interstitial cystitis
PCT/US2011/039550 WO2011156445A1 (en) 2010-06-08 2011-06-08 Applications of partially and fully sulfated hyaluronan
USPCT/US11/39550 2011-06-08
PCT/US2012/030233 WO2012129461A1 (en) 2011-03-23 2012-03-23 Methods for treating or preventing urological inflammation

Publications (1)

Publication Number Publication Date
CA2830933A1 true CA2830933A1 (en) 2012-09-27

Family

ID=46879753

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2830933A Abandoned CA2830933A1 (en) 2011-03-23 2012-03-23 Methods for treating or preventing urological inflammation

Country Status (7)

Country Link
US (2) US9522162B2 (https=)
EP (1) EP2688402B1 (https=)
JP (1) JP6062917B2 (https=)
AU (1) AU2012230822A1 (https=)
CA (1) CA2830933A1 (https=)
IL (1) IL228605A0 (https=)
WO (1) WO2012129461A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009231634B2 (en) 2008-04-04 2014-05-15 University Of Utah Research Foundation Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
US11337994B2 (en) 2016-09-15 2022-05-24 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
US10849914B2 (en) 2017-06-12 2020-12-01 University Of Utah Research Foundation Methods for producing chemoembolic agents for the delivery of anti-cancer agents
CN111228653A (zh) 2018-11-13 2020-06-05 格莱科米拉治疗公司 用电离辐射加强癌症治疗的方法
WO2021133000A1 (ko) * 2019-12-23 2021-07-01 주식회사 엘지화학 항염 또는 항혈관신생용 약제학적 조성물
KR102466631B1 (ko) * 2021-07-13 2022-11-14 에스비바이오팜 주식회사 하부 요로계 애완동물 소프트사료의 제조방법
CN113754795B (zh) * 2021-10-19 2023-03-10 澳门大学 磺酸化透明质酸类化合物、其制备方法及其应用
CN116990101B (zh) * 2023-09-27 2023-12-15 四川大学华西医院 一种易掉片组织的预处理方法及其多重免疫荧光染色方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2599172A (en) 1948-11-29 1952-06-03 Searle & Co Sulfuric acid esters of hyaluronic acid and processes for the production thereof
US4240163A (en) 1979-01-31 1980-12-23 Galin Miles A Medicament coated intraocular lens
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
FR2584728B1 (fr) 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
SE453394B (sv) 1986-07-07 1988-02-01 Pharmacia Ab Forfarande for framstellning av sulfaterade polysackarider genom anvendning av ett reducerande medel for sulfateringsreaktionen
EP0285357A3 (en) 1987-03-31 1989-10-25 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Control of retroviruses
DK505588D0 (da) 1988-02-26 1988-09-09 Jesper Hamburger Middel og anvendelse af samme
IT1217458B (it) 1988-05-02 1990-03-22 Crinos Ind Farmacoriologica S Sulfoamino derivati di condroitin solfati,del dermatan solfato e dell' acido ialuronico e loro proprieta' farmacologiche
IT1247175B (it) 1991-04-19 1994-12-12 Fidia Spa Procedimento per la purificazione di acido ialuronico e frazione di acido ialuronico puro per uso oftalmico.
ES2149178T3 (es) 1991-08-16 2000-11-01 Miles A Galin Implante ocular para la camara anterior refractivo, recubierto con un medicamento.
ITPD940054A1 (it) 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
DE69621528T2 (de) 1995-02-07 2003-01-16 Shiseido Co. Ltd., Tokio/Tokyo Anti-inflamatorische agenzien
GB2317182B (en) 1996-09-11 2000-11-01 Johnson & Johnson Medical Sulfated polysaccharides and uses thereof in medical treatment
JPH10195107A (ja) 1997-01-10 1998-07-28 Shiseido Co Ltd オリゴ硫酸化ヒアルロン酸
DK0971961T3 (da) 1997-04-04 2003-03-24 Fidia Advanced Biopolymers Srl N-sulfaterede hyaluronsyreforbindelser, derivater deraf og en fremgangsmåde til deres fremstilling
US5981509A (en) 1997-05-20 1999-11-09 Shiseido Company, Ltd. Preparation for prophylaxis or treatment of renal diseases containing sulfated polysaccharide
IT1293484B1 (it) 1997-06-11 1999-03-01 Fidia Advanced Biopolymers Srl Materiale biologico comprendente una efficiente coltura di cellule e una matrice tridimensionale biocompatibile e biodegradabile
IT1294797B1 (it) 1997-07-28 1999-04-15 Fidia Advanced Biopolymers Srl Uso dei derivati dell'acido ialuronico nella preparazione di biomateriali aventi attivita' emostatica fisica e tamponante
ITPD980037A1 (it) 1998-02-25 1999-08-25 Fidia Advanced Biopolymers Srl Acido ialuronico solfatato e i suoi derivati legati covalentemente a polimeri sintetici pe la preparazione di biomateriali e per il rivesti
JPH11269077A (ja) 1998-03-19 1999-10-05 Maruho Co Ltd ホスホリパーゼａ２阻害用医薬組成物
DE19813234A1 (de) 1998-03-26 1999-09-30 Knoell Hans Forschung Ev Verfahren zur Herstellung hochsulfatierter Hyaluronsäuren
JPH11279042A (ja) 1998-03-30 1999-10-12 Shiseido Co Ltd 皮膚外用剤
US6984667B2 (en) 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
ITPD980149A1 (it) 1998-06-17 1999-12-17 Fidia Advanced Biopolymers Srl Protesi tridimensionali comprendenti derivati dell'acido ialuronico per riparare o ricostruire i tessuti danneggiati e processo per la
US6492503B1 (en) 1998-07-31 2002-12-10 Seikagaku Corporation Glycosaminoglycan and drug compositions containing the same
IT1303735B1 (it) 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
IT1306644B1 (it) 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Strutture tridimensionali comprendenti derivati dell'acido ialuronicoottenibili mediante la tecnica antisolvente supercritico.
US6288043B1 (en) 1999-06-18 2001-09-11 Orquest, Inc. Injectable hyaluronate-sulfated polysaccharide conjugates
JP2001097997A (ja) 1999-10-01 2001-04-10 Shiseido Co Ltd 硫酸化ヒアルロン酸を用いたアフィニティー吸着担体及びその使用
JP2001163789A (ja) 1999-12-13 2001-06-19 Maruho Co Ltd マトリックスメタロプロテアーゼ阻害用医薬組成物
EP1471870B1 (en) 2000-01-10 2014-08-20 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
NZ521369A (en) 2000-03-17 2004-07-30 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6828308B2 (en) 2000-07-28 2004-12-07 Sinclair Pharmaceuticals, Ltd. Compositions and methods for the treatment or prevention of inflammation
IT1317359B1 (it) 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl Polisaccaridi percarbossilati, quali l'acido ialuronico, processo perla loro preparazione e loro impiego in campo farmaceutico e
DE10053053A1 (de) 2000-10-19 2002-05-16 Knoell Hans Forschung Ev Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden
ITPD20020064A1 (it) 2002-03-12 2003-09-12 Fidia Advanced Biopolymers Srl Derivati esterei dell'acido ialuronico per la preparazione di idrogelda utilizzare in campo biomedico, sanitario e chirurgico e come sistem
WO2003086474A2 (en) 2002-04-11 2003-10-23 Carbomer, Inc Fluorinated or paramagnetic alginate polymer, annexin paramagnetic conjugate, and their use as contrasting agent in mri
US7030208B2 (en) 2002-04-11 2006-04-18 Carbomer, Inc. Biocompatible materials and probes
RU2005102604A (ru) 2002-07-03 2005-09-10 Перикор Сайенс, Инк. (Us) Композиция гиалуроновой кислоты и способы применения
DE10352137A1 (de) 2003-11-04 2005-06-16 Beschorner, Katharina, Dr. Verwendung sulfatierter Hyaluronsäure
EP1694712A1 (en) 2003-12-04 2006-08-30 University of Utah Research Foundation Modified macromolecules and methods of making and using thereof
US20050203056A1 (en) 2003-12-19 2005-09-15 Aventis Pharma S.A. Carboxyl-reduced derivatives of hyaluronic acid, preparation thereof, use thereof as a medicinal product and the pharmaceutical compositions containing them
FR2864090B1 (fr) 2003-12-19 2006-01-27 Aventis Pharma Sa Derives carboxy-reduits de l'acide hyaluronique, leur preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant
ITPD20040245A1 (it) 2004-10-08 2005-01-08 Fidia Advanced Biopolymers Srl Biomateriali costituiti da acido ialuronico solfatato e gellano utilizzabili nella prevenzione delle adesioni spinali
DE102005004643B4 (de) 2005-01-28 2010-04-08 Innovent E.V. Technologieentwicklung Antivirale Kombinationen sowie ihre Verwendung
JP2006206849A (ja) 2005-01-31 2006-08-10 Seikagaku Kogyo Co Ltd アルキルエステル化されたグリコサミノグリカンの製造方法
US20090105463A1 (en) 2005-03-29 2009-04-23 Massachusetts Institute Of Technology Compositions of and Methods of Using Oversulfated Glycosaminoglycans
WO2006108022A1 (en) 2005-04-04 2006-10-12 Neoparin, Inc. Process for the induction of intramolecular migration of sulfates, phosphates, and other oxyanions
ITPD20050206A1 (it) 2005-07-07 2007-01-08 Fidia Advanced Biopolymers Srl Biomateriali in forma di fibra da impiegarsi come dispositivi medici nel trattamento delle ferite e loro processi di produzione
US7993678B2 (en) 2005-09-26 2011-08-09 Novozymes Biopolymer A/S Hyaluronic acid derivatives
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
US20080306022A1 (en) 2005-10-12 2008-12-11 Kenji Miyamoto Agent for Applying to Mucosa and Method for the Production Thereof
DE602006019474D1 (de) 2005-11-22 2011-02-17 Ard Sa Hren dafür und verwendungen davon
US20070166266A1 (en) 2006-01-19 2007-07-19 Solazyme, Inc. Methods and compositions for improving the health and appearance of skin
DK1994062T3 (da) 2006-03-02 2009-11-16 Novozymes Biopharma Dk As Aryl/alkyl-vinylsulfonhyaluronsyrederivater
ITPD20060219A1 (it) 2006-05-31 2007-12-01 Fidia Farmaceutici Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi
US20080032920A1 (en) 2006-07-11 2008-02-07 Prestwich Glenn D Macromolecules modified with electrophilic groups and methods of making and using thereof
EP2070518A2 (en) 2006-07-25 2009-06-17 Osmotica Corp. Ophthalmic solutions
TW200838552A (en) 2007-01-25 2008-10-01 Novozymes Biopolymer As Methyl esters of hyaluronic acid
JP5088864B2 (ja) 2007-03-16 2012-12-05 オリンパス株式会社 生体組織補填材とその製造方法
EP2025687A1 (en) 2007-07-23 2009-02-18 Istituto Scientifico di Chimica E Biochimica "G Ronzoni Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby
EP2057983A1 (en) 2007-11-07 2009-05-13 Bruschettini S.r.l. Compositions for the topical protection of the ocular tissues from the damaging effects of ultraviolet radiations
US8093365B2 (en) 2008-03-03 2012-01-10 New York University Biocompatible materials containing stable complexes method of TSG-6 and hyaluronan and method of using same
AU2009231634B2 (en) * 2008-04-04 2014-05-15 University Of Utah Research Foundation Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
US8343942B2 (en) 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
BRPI1007325A2 (pt) 2009-02-02 2019-09-24 Otsuka Pharma Co Ltd "baixo peso molecular de polissulfatados derivados de ácido hialurônico e medicamentos que contenham o mesmo."
US20100204325A1 (en) 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
IT1393945B1 (it) 2009-04-21 2012-05-17 Fidia Farmaceutici Composizioni comprendenti acido ialuronico, acido ialuronico solfatato, calcio e vitamina d3 nel trattamento delle malattie osteoarticolari e muscoloscheletriche
IT1397247B1 (it) 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi agenti regolatori dell'attivita' citochinica
IT1397246B1 (it) 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica

Also Published As

Publication number Publication date
IL228605A0 (en) 2013-12-31
US20140343011A1 (en) 2014-11-20
AU2012230822A2 (en) 2013-11-28
JP2014511841A (ja) 2014-05-19
EP2688402A4 (en) 2014-09-24
US10226481B2 (en) 2019-03-12
US20170095501A1 (en) 2017-04-06
JP6062917B2 (ja) 2017-01-18
US9522162B2 (en) 2016-12-20
EP2688402B1 (en) 2018-10-24
EP2688402A1 (en) 2014-01-29
WO2012129461A1 (en) 2012-09-27
AU2012230822A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
US8343942B2 (en) Methods for treating interstitial cystitis
US10226481B2 (en) Pharmaceutical compositions composed of low molecular weight sulfated hyaluronan
US8399430B2 (en) Alkylated semi synthetic glycosaminoglycosan ethers, and methods for making and using thereof
US10179147B2 (en) Applications of partially and fully sulfated hyaluronan
ES2367778T3 (es) Derivados de glucosaminoglucanos parcialmente desulfatados como inhibidores de heparanasa, provistos de actividad antiangiogénica y desprovistos de efecto anticoagulante.
CN102114031B (zh) 使用于炎症性肠疾病治疗和预防的透明质酸混合物
Jhundoo et al. Hyaluronic acid increases anti-inflammatory efficacy of rectal 5-amino salicylic acid administration in a murine colitis model
KR20140042795A (ko) 비뇨기 염증을 치료 또는 예방하는 방법
CN114650828B (zh) 药物组合物
JP2000513707A (ja) 投与薬剤の目標化、治療薬および他のグリコサミノグリカン（ｇａｇｓ）
HK1157800A (en) Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170317

FZDE Discontinued

Effective date: 20200831